MDS | Tumor

CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.

So You Have Cancer, Eat the Donut

September 26th 2017, 5:45am

Article

Cancer survivors generally work very hard to be healthy after a diagnosis. This article gives permission to enjoy life and have a balanced attitude toward healthy living.

Cancer, One Step at a Time

September 21st 2017, 6:58am

Article

How one cancer survivor attempts to cope with the reality of having chemo for the rest of her life.

Why Blood Counts Matter in Myelodysplastic Syndrome

September 15th 2017, 9:42pm

Article

Injured DNA can hide damaged blood cells in myelodysplastic syndrome (MDS).

Chemo Fog Is Real and Scary

September 1st 2017, 5:54am

Article

Chemo fog, or chemo brain, is a very real phenomena that cancer survivors need to be knowledgeable about. This describes the journey of one survivor.

Collaboration Is Key in MDS Research

August 24th 2017, 4:53pm

Article

CURE spoke with Rami S. Komrokji, M.D. about collaborative efforts that will lead to new advances in the treatment of myelodysplastic syndrome (MDS).

Tips for Battling Cancer

August 17th 2017, 12:01am

Article

Making Progress for Myelodysplastic Syndrome

July 25th 2017, 7:15pm

Article

In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.

The Roller Coaster of MDS

July 14th 2017, 7:09am

Article

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS.

Filling an Unmet Need in MDS Treatment

July 7th 2017, 7:25pm

Video

Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).

Younger Patients With AML and MDS Best Suited for Intensive Preparatory Regimen Before Stem Cell Transplant

July 7th 2017, 6:49pm

Article

An intensive preparatory stem cell transplant (SCT) regimen should be used for younger patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to the results of a phase 3 clinical trial.